Neumora Therapeutics(NMRA) - 2024 Q4 - Annual Results

Exhibit 99.1 Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 in Alzheimer's disease agitation expected by the end of 2025 Expect to progress next M4 positive allosteric modulator (PAM) program into the clinic by mid-2025 Strong financial position wit ...